

Maria JosÃ© Santos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6198076/publications.pdf>

Version: 2024-02-01

152
papers

3,924
citations

172443

29
h-index

144002

57
g-index

172
all docs

172
docs citations

172
times ranked

5697
citing authors

#	ARTICLE	IF	CITATIONS
1	Underdetection of Interstitial Lung Disease in Juvenile Systemic Sclerosis. Arthritis Care and Research, 2022, 74, 364-370.	3.4	13
2	Differences Sustained Between Diffuse and Limited Forms of Juvenile Systemic Sclerosis in an Expanded International Cohort. Arthritis Care and Research, 2022, 74, 1575-1584.	3.4	13
3	Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries. Arthritis Care and Research, 2022, 74, 1205-1218.	3.4	20
4	Gender differences in clinical features and outcomes of a Portuguese systemic sclerosis cohort. Clinical Rheumatology, 2022, 41, 1139-1144.	2.2	5
5	Antigonon leptopus invasion is associated with plant community disassembly in a Caribbean island ecosystem. Biological Invasions, 2022, 24, 353-371.	2.4	2
6	EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology. Annals of the Rheumatic Diseases, 2022, 81, 780-785.	0.9	12
7	Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. Annals of the Rheumatic Diseases, 2022, 81, 970-978.	0.9	49
8	The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis. Rheumatology, 2022, 61, 4741-4751.	1.9	6
9	European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response. Rheumatology, 2022, 61, 3799-3807.	1.9	7
10	Using Patient-Reported Outcome Measures to Evaluate Care for Patients With Inflammatory Chronic Rheumatic Disease. Value in Health, 2022, 25, 1885-1893.	0.3	1
11	Spotlight on latent tuberculosis infection screening for juvenile idiopathic arthritis in two countries, comparing high and low risk patients. Advances in Rheumatology, 2022, 62, .	1.7	1
12	Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the â€œJAK-potâ€™ collaboration. Annals of the Rheumatic Diseases, 2022, 81, 1358-1366.	0.9	48
13	The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries. Rheumatology, 2021, 60, 820-828.	1.9	41
14	Atherosclerosis and Bone Loss in Humansâ€“Results From Deceased Donors and From Patients Submitted to Carotid Endarterectomy. Frontiers in Medicine, 2021, 8, 672496.	2.6	4
15	Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration. Annals of the Rheumatic Diseases, 2021, 80, 1410-1418.	0.9	28
16	Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Annals of the Rheumatic Diseases, 2021, 80, 930-942.	0.9	496
17	Health-related quality of life and disability in adults with juvenile idiopathic arthritis: comparison with adult-onset rheumatic diseases. RMD Open, 2021, 7, e001766.	3.8	11
18	Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatology. RMD Open, 2021, 7, e001818.	3.8	4

#	ARTICLE	IF	CITATIONS
19	Association of body mass index with Juvenile Idiopathic Arthritis disease activity: a Portuguese and Brazilian collaborative analysis. Acta ReumatolÃ³gica Portuguesa, 2021, 46, 7-14.	0.2	0
20	Granulomatosis with polyangiitis - the incomplete puzzle.. Acta ReumatolÃ³gica Portuguesa, 2021, 46, 350-354.	0.2	0
21	Clinical images of ENT involvement in ANCA associated Vasculitis.. Acta ReumatolÃ³gica Portuguesa, 2021, 46, 363-364.	0.2	0
22	Real-world Longterm Effectiveness of Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis Patients from the Rheumatic Diseases Portuguese Register. Journal of Rheumatology, 2020, 47, 690-700.	2.0	15
23	Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis. Seminars in Arthritis and Rheumatism, 2020, 50, 17-24.	3.4	19
24	Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatmentâ€”results from 12 countries in EuroSpA. Rheumatology, 2020, 59, 1640-1650.	1.9	18
25	P131â€œBelimumab in the treatment of 38 portuguese SLE patients: a real-life multicentric study. , 2020, , .		0
26	Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration. RMD Open, 2020, 6, e001280.	3.8	33
27	Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respiratory Medicine,the, 2020, 8, 963-974.	10.7	348
28	Safety and Effectiveness of Biologic Disease-Modifying Antirheumatic Drugs in Older Patients with Rheumatoid Arthritis: A Prospective Cohort Study. Drugs and Aging, 2020, 37, 899-907.	2.7	7
29	Reuma.pt/vasculitis â€œ the Portuguese vasculitis registry. Orphanet Journal of Rare Diseases, 2020, 15, 110.	2.7	11
30	Impact of discordance between patientâ€™s and evaluatorâ€™s global assessment on treatment outcomes in 14 868 patients with spondyloarthritis. Rheumatology, 2020, 59, 2455-2461.	1.9	7
31	Toll-like receptor 3 increases antigen-presenting cell responses to a pro-apoptotic stimulus, yet does not contribute to systemic lupus erythematosus genetic susceptibility. Clinical and Experimental Rheumatology, 2020, 38, 881-890.	0.8	1
32	How did COVID-19 pandemic changed the Portuguese rheumatology?. Acta ReumatolÃ³gica Portuguesa, 2020, 45, 5-6.	0.2	0
33	Development and validation of psoriatic arthritis switch quality assessment tool (PASQAL) - an outcomes measurement tool to assess the quality of biologic switch decisions in psoriatic arthritis. Acta ReumatolÃ³gica Portuguesa, 2020, 45, 46-57.	0.2	0
34	Juvenile bullous systemic lupus erythematosus - case report. Acta ReumatolÃ³gica Portuguesa, 2020, 45, 74-75.	0.2	0
35	Early retirement attributed to rheumatoid arthritis and its predictors. Acta ReumatolÃ³gica Portuguesa, 2020, 45, 177-182.	0.2	0
36	Belimumab in the treatment of Portuguese Systemic Lupus Erythematosus patients: a real-life multicenter study. Acta ReumatolÃ³gica Portuguesa, 2020, 45, 170-176.	0.2	0

#	ARTICLE	IF	CITATIONS
37	Remission and low disease activity matrix tools: results in real-world rheumatoid arthritis patients under anti-TNF therapy. Acta Reumatol 3 gica Portuguesa, 2020, 45, 245-252.	0.2	2
38	Are diffuse and limited juvenile systemic sclerosis different in clinical presentation? Clinical characteristics of a juvenile systemic sclerosis cohort. Journal of Scleroderma and Related Disorders, 2019, 4, 49-61.	1.7	20
39	Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts. Annals of the Rheumatic Diseases, 2019, 78, 1545-1549.	0.9	71
40	Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration. Annals of the Rheumatic Diseases, 2019, 78, 1536-1544.	0.9	58
41	Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution. Rheumatology, 2019, 58, 2221-2229.	1.9	11
42	Rituximab in connective tissue disease—associated interstitial lung disease. Clinical Rheumatology, 2019, 38, 2001-2009.	2.2	36
43	Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open-Label Trial. Arthritis and Rheumatology, 2019, 71, 1616-1625.	5.6	14
44	AB0967—IS THERE A DIFFERENCE IN PRESENTATION OF FEMALE AND MALE PATIENTS WITH JUVENILE SYSTEMIC SCLERODERMA. AN UPDATE FROM THE JUVENILE SYSTEMIC SCLERODERMA INCEPTION COHORT. WWW.JUVENILE-SCLERODERMA.COM. , 2019, , .		0
45	OP0245—PRESERVATION OF LUNG FUNCTION OBSERVED IN A PHASE 3 RANDOMIZED CONTROLLED TRIAL OF TOCILIZUMAB FOR THE TREATMENT OF EARLY SSC. , 2019, , .		5
46	AB0503—THE LUNG IN SJÖ–GREN’S SYNDROME PATIENTS — AN OVERVIEW OF CLINICAL CHARACTERISTICS AND DISEASE OUTCOME. , 2019, , .		0
47	FRI0404—POOLED 6-MONTH TREATMENT OUTCOMES AND DRUG RETENTION RATES IN 1556 PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH SECUKINUMAB IN ROUTINE CLINICAL PRACTICE IN 12 EUROPEAN COUNTRIES IN THE EUROSPA RESEARCH COLLABORATION. , 2019, , .		1
48	AB0752—DRUG RETENTION AND REMISSION RATES IN 14,261 BIOLOGIC-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS STARTING TNF INHIBITOR TREATMENT IN ROUTINE CARE — RESULTS FROM 12 REGISTRIES IN THE EUROSPA RESEARCH COLLABORATION. , 2019, , .		0
49	SAT0391—REMISSION AND DRUG RETENTION RATES OF SECUKINUMAB IN 1549 PATIENTS WITH PSORIATIC ARTHRITIS TREATED IN ROUTINE CARE — POOLED DATA FROM THE OBSERVATIONAL EUROSPA RESEARCH COLLABORATION NETWORK. , 2019, , .		0
50	SAT0479—UPDATE FROM THE JUVENILE SCLERODERMA INCEPTION COHORT. WWW.JUVENILE-SCLERODERMA.COM. , 2019, , .		0
51	SAT0478—AFTER 24 MONTHS OBSERVATION PERIOD THE PATIENTS RELATED OUTCOMES IMPROVE SIGNIFICANTLY IN THE JUVENILE SCLERODERMA INCEPTIONS COHORT. WWW.JUVENILE-SCLERODERMA.COM. , 2019, , .		0
52	SAT0366—GENDER DIFFERENCES IN PSORIATIC ARTHRITIS — IMPACT ON TUMOR NECROSIS FACTOR INHIBITORS PERSISTENCE AND RESPONSE. , 2019, , .		1
53	FRI0378—DOES DRUG EFFECTIVENESS OF 2ND AND 3RD TNF INHIBITORS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS DEPEND ON THE REASON FROM WITHDRAWAL FROM THE PREVIOUS TREATMENT? — RESULTS FROM THE EUROSPA RESEARCH COLLABORATION. , 2019, , .		3
54	SAT0143—SAFETY AND EFFECTIVENESS OF BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN ELDERLY PATIENTS WITH RHEUMATOID ARTHRITIS. , 2019, , .		1

#	ARTICLE	IF	CITATIONS
55	SAT0509â€¦...BODY MASS INDEX AND DISEASE ACTIVITY IN PORTUGUESE AND BRAZILIAN JUVENILE IDIOPATHIC ARTHRITIS PATIENTS: RESULTS FROM RHEUMATIC DISEASES PORTUGUESE REGISTER â€œ REUMA.PT. , 2019, , .		0
56	FRI0453â€¦...DOES DISCORDANCE BETWEEN BASELINE PATIENTâ€™S AND EVALUATORâ€™S GLOBAL ASSESSMENT OF DISEASE ACTIVITY IMPACT RETENTION AND REMISSION RATES OF TNF INHIBITORS IN PATIENTS WITH PSORIATIC ARTHRITIS? DATA FROM THE EUROSPA RESEARCH COLLABORATION. , 2019, , .		0
57	OP0031â€¦...ARE THE MODIFIED NEW YORK AND ASAS AXIAL SPONDYLOARTHRITIS CRITERIA INTERCHANGEABLE IN THE CLASSIFICATION OF SPONDYLOARTHRITIS PATIENTS WITH RADIOGRAPHIC SACROILIITIS: COMPARISON IN 8 COHORTS?. , 2019, , .		0
58	Imputing missing data of function and disease activity in rheumatoid arthritis registers: what is the best technique?. RMD Open, 2019, 5, e000994.	3.8	22
59	Lung function preservation in a phase 3 trial of tocilizumab (TCZ) in systemic sclerosis (SSc). , 2019, , .		2
60	Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor in rheumatoid arthritis patients who discontinued a first TNF inhibitor. Acta ReumatolÃ³gica Portuguesa, 2019, 44, 103-113.	0.2	4
61	Predictors and causes of first-line biologic agent discontinuation in rheumatoid arthritis: data from Reuma.pt. Acta ReumatolÃ³gica Portuguesa, 2019, 44, 57-64.	0.2	5
62	How to diagnose lupus enteritis early? Lessons learned from a multicenter case series. Acta ReumatolÃ³gica Portuguesa, 2019, 44, 145-150.	0.2	1
63	Biologic therapy use and pregnancy outcomes in women with immune-mediated inflammatory rheumatic diseases. Acta ReumatolÃ³gica Portuguesa, 2019, 44, 266-272.	0.2	2
64	The burden and undertreatment of fragility fractures among senior women. Archives of Osteoporosis, 2018, 13, 22.	2.4	19
65	2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2018, 77, 476-479.	0.9	47
66	Anti-fibrotic nintedanibâ€™a new opportunity for systemic sclerosis patients?. Clinical Rheumatology, 2018, 37, 1123-1127.	2.2	10
67	Water primrose invasion changes successional pathways in an estuarine ecosystem. Ecosphere, 2018, 9, e02418.	2.2	18
68	Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries. RMD Open, 2018, 4, e000809.	3.8	17
69	Comparing the Potential of Multispectral and Hyperspectral Data for Monitoring Oil Spill Impact. Sensors, 2018, 18, 558.	3.8	26
70	Challenges of Ageing in Portugal: Data from the EpiDoC Cohort. Acta Medica Portuguesa, 2018, 31, 80-93.	0.4	33
71	Common Evaluations of Disease Activity in Rheumatoid Arthritis Reach Discordant Classifications across Different Populations. Frontiers in Medicine, 2018, 5, 40.	2.6	26
72	Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration. Annals of the Rheumatic Diseases, 2018, 77, 1276-1282.	0.9	51

#	ARTICLE	IF	CITATIONS
73	Reuma.pt - structure and innovation. Acta ReumatolÃ³gica Portuguesa, 2018, 43, 8-9.	0.2	1
74	Safety of Etanercept in the treatment of rheumatic disease patients with Hepatitis C virus infection. Acta ReumatolÃ³gica Portuguesa, 2018, 43, 159-160.	0.2	1
75	Iloprost infusion through elastomeric pump for the outpatient treatment of severe Raynaud's phenomenon and digital ulcers - a single centre experience. Acta ReumatolÃ³gica Portuguesa, 2018, 43, 237-238.	0.2	3
76	Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration. Journal of Rheumatology, 2017, 44, 162-169.	2.0	17
77	A survey of national and multi-national registries and cohort studies in juvenile idiopathic arthritis: challenges and opportunities. Pediatric Rheumatology, 2017, 15, 31.	2.1	27
78	Letter to the Editor: Therapies for Osteogenesis Imperfecta. Acta Medica Portuguesa, 2017, 30, 156.	0.4	1
79	Juvenile Systemic Sclerosis: Review of 17 Portuguese Patients. Journal of Scleroderma and Related Disorders, 2017, 2, 121-126.	1.7	2
80	Home-Based Intervention Program to Reduce Food Insecurity in Elderly Populations Using a TV App: Study Protocol of the Randomized Controlled Trial SaÃ³de.Come Senior. JMIR Research Protocols, 2017, 6, e40.	1.0	13
81	Predictors of response to TNF blockers in patients with polyarticular psoriatic arthritis. Acta ReumatolÃ³gica Portuguesa, 2017, 42, 55-65.	0.2	4
82	Real-life effectiveness of Golimumab in biologic-naÃve patients with rheumatoid arthritis - data from the Rheumatic Diseases Portuguese Register (Reuma.pt). Acta ReumatolÃ³gica Portuguesa, 2017, 42, 141-149.	0.2	4
83	Where are the vertebrae?. Acta ReumatolÃ³gica Portuguesa, 2017, 42, 273-274.	0.2	0
84	Reuma.pt contribution to the knowledge of immune-mediated systemic rheumatic diseases. Acta ReumatolÃ³gica Portuguesa, 2017, 42, 232-239.	0.2	2
85	Effectiveness of early adalimumab therapy in psoriatic arthritis patients from Reuma.pt - EARLY PsA. Acta ReumatolÃ³gica Portuguesa, 2017, 42, 287-299.	0.2	1
86	Reuma.pt â a case study. Acta Medica Portuguesa, 2016, 29, 83.	0.4	7
87	Juvenile idiopathic arthritis in adulthood: fulfilment of classification criteria for adult rheumatic diseases, long-term outcomes and predictors of inactive disease, functional status and damage. RMD Open, 2016, 2, e000304.	3.8	47
88	Clinical features and long-term outcomes of systemic lupus erythematosus: comparative data of childhood, adult and late-onset disease in a national register. Rheumatology International, 2016, 36, 955-960.	3.0	44
89	Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort Study. EBioMedicine, 2016, 11, 302-306.	6.1	27
90	International multi-center evaluation of a novel chemiluminescence assay for the detection of anti-dsDNA antibodies. Lupus, 2016, 25, 864-872.	1.6	26

#	ARTICLE	IF	CITATIONS
91	Effectiveness and long-term retention of anti-tumour necrosis factor treatment in juvenile and adult patients with juvenile idiopathic arthritis: data from Reuma.pt. Rheumatology, 2016, 55, 697-703.	1.9	21
92	Identifying Patient Candidates for IL-1 Inhibition: Lessons From Real-World Cases. Joint Bone Spine, 2015, 82, eS17-eS29.	1.6	7
93	TRAF1/C5 but Not PTPRC Variants Are Potential Predictors of Rheumatoid Arthritis Response to Anti-Tumor Necrosis Factor Therapy. BioMed Research International, 2015, 2015, 1-9.	1.9	15
94	Genetic Predictors of Poor Prognosis in Portuguese Patients with Juvenile Idiopathic Arthritis: Data from Reuma.pt. Journal of Immunology Research, 2015, 2015, 1-6.	2.2	3
95	Comparative Effectiveness of Tocilizumab and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from the Rheumatic Diseases Portuguese Register, Reuma.pt. BioMed Research International, 2015, 2015, 1-13.	1.9	19
96	Esclerose Sist�mica Juvenil. Acta Medica Portuguesa, 2015, 28, 785.	0.4	0
97	Classification of Systemic Lupus Erythematosus: Systemic Lupus International Collaborating Clinics Versus American College of Rheumatology Criteria. A Comparative Study of 2,055 Patients From a Real-Life, International Systemic Lupus Erythematosus Cohort. Arthritis Care and Research, 2015, 67, 1180-1185.	3.4	125
98	Characterization of damage in Portuguese lupus patients: analysis of a national lupus registry. Lupus, 2015, 24, 256-262.	1.6	26
99	The weaker sex: Characterization of gender disparities in a nationwide lupus register (Reuma.pt/SLE). Joint Bone Spine, 2015, 82, 378-380.	1.6	0
100	DAS28, CDAI and SDAI cut-offs do not translate the same information: results from the Rheumatic Diseases Portuguese Register Reuma.pt. Rheumatology, 2015, 54, 286-291.	1.9	22
101	Immune-Mediated Inflammatory Rheumatic Diseases. , 2015, , 113-132.		0
102	PORTUGUESE RECOMMENDATIONS FOR THE USE OF BIOLOGICAL THERAPIES IN PATIENTS WITH PSORIATIC ARTHRITIS-2015 UPDATE. Acta Reumatol�gica Portuguesa, 2015, 40, 275-90.	0.2	2
103	Acute acalculous cholecystitis in a patient with juvenile dermatomyositis. BMJ Case Reports, 2014, 2014, bcr2014205066-bcr2014205066.	0.5	8
104	Using the Juvenile Arthritis Disease Activity Score Based on Erythrocyte Sedimentation Rate or C-reactive Protein Level: Results From the Portuguese Register. Arthritis Care and Research, 2014, 66, 585-591.	3.4	17
105	Lack of replication of higher genetic risk load in men than in women with systemic lupus erythematosus. Arthritis Research and Therapy, 2014, 16, R128.	3.5	11
106	Broadened T-cell Repertoire Diversity in ivlg-treated SLE Patients is Also Related to the Individual Status of Regulatory T-cells. Journal of Clinical Immunology, 2013, 33, 349-360.	3.8	22
107	Anti-ribosomal P protein IgG autoantibodies in patients with systemic lupus erythematosus: diagnostic performance and clinical profile. BMC Medicine, 2013, 11, 98.	5.5	50
108	A10.5����Comparative Effectiveness of Biological Therapies in Rheumatoid Arthritis is Influenced by Response Measures and Disease Activity State. Annals of the Rheumatic Diseases, 2013, 72, A73.1-A73.	0.9	0

#	ARTICLE	IF	CITATIONS
109	A7.16â€¦Lack of Replication of<i>PTPRC Gene</i>as a Predictor of Response to Anti-Tumour Necrosis Factor Therapy in Patients with Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A53.2-A53.	0.9	1
110	Systemic rheumatic diseases: beyond classification criteria. <i>Acta ReumatolÃ³gica Portuguesa</i> , 2013, 38, 7-8.	0.2	0
111	Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis. <i>Rheumatology</i> , 2012, 51, 2020-2026.	1.9	78
112	TRAF1/C5 locus is associated with response to anti-TNF in rheumatoid arthritis. <i>Journal of Translational Medicine</i> , 2012, 10, .	4.4	2
113	Bias in effect size of systemic lupus erythematosus susceptibility loci across Europe: a case-control study. <i>Arthritis Research and Therapy</i> , 2012, 14, R94.	3.5	8
114	Early Vascular Alterations in SLE and RA Patientsâ€™A Step towards Understanding the Associated Cardiovascular Risk. <i>PLoS ONE</i> , 2012, 7, e44668.	2.5	45
115	Further Evidence of Subphenotype Association with Systemic Lupus Erythematosus Susceptibility Loci: A European Cases Only Study. <i>PLoS ONE</i> , 2012, 7, e45356.	2.5	28
116	10.4172/2167-7921.1000e106. <i>Journal of Arthritis</i> , 2012, 01, .	0.3	0
117	TNF promoter -308 G>A and LTA 252 A>G polymorphisms in Portuguese patients with systemic lupus erythematosus. <i>Rheumatology International</i> , 2012, 32, 2239-2244.	3.0	18
118	Plant community dynamics relative to the changing distribution of a highly invasive species, <i>Eichhornia crassipes</i> : a remote sensing perspective. <i>Biological Invasions</i> , 2012, 14, 717-733.	2.4	33
119	Portuguese recommendations for the use of biological therapies in children and adolescents with juvenile idiopathic arthritisâ€”December 2011 update. <i>Acta ReumatolÃ³gica Portuguesa</i> , 2012, 37, 48-68.	0.2	1
120	An integrated approach to a biophysically based classification of floating aquatic macrophytes. <i>International Journal of Remote Sensing</i> , 2011, 32, 1067-1094.	2.9	68
121	Soluble receptor activator of nuclear factor Î²B ligand/osteoprotegerin ratio is increased in systemic lupus erythematosus patients. <i>Arthritis Research and Therapy</i> , 2011, 13, R175.	3.5	19
122	Hemorheological parameters are related to subclinical atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis patients. <i>Atherosclerosis</i> , 2011, 219, 821-826.	0.8	40
123	Effects of invasive species on plant communities: an example using submersed aquatic plants at the regional scale. <i>Biological Invasions</i> , 2011, 13, 443-457.	2.4	89
124	Interleukin-6 promoter polymorphism â€™174 G/C is associated with nephritis in Portuguese Caucasian systemic lupus erythematosus patients. <i>Clinical Rheumatology</i> , 2011, 30, 409-413.	2.2	28
125	Development of amyloidosis in patients with rheumatoid arthritis under TNF-blocking agents. <i>Clinical Rheumatology</i> , 2011, 30, 869-870.	2.2	4
126	Predictors of response and anti-TNF drugs comparative efficacy. <i>Journal of Translational Medicine</i> , 2011, 9, .	4.4	0

#	ARTICLE	IF	CITATIONS
127	Active regulatory T-cells contribute to broadened T-cell repertoire diversity in ivlg-treated SLE patients. <i>Journal of Translational Medicine</i> , 2011, 9, .	4.4	1
128	Lymphotoxin- α 252 A>G Polymorphism: A Link Between Disease Susceptibility and Dyslipidemia in Rheumatoid Arthritis?. <i>Journal of Rheumatology</i> , 2011, 38, 1244-1249.	2.0	16
129	Association of Systemic Lupus Erythematosus Clinical Features with European Population Genetic Substructure. <i>PLoS ONE</i> , 2011, 6, e29033.	2.5	14
130	Patients' satisfaction with the rheumatology day care unit. <i>Acta ReumatolÃ³gica Portuguesa</i> , 2011, 36, 377-84.	0.2	4
131	Portuguese guidelines for the use of biological agents in rheumatoid arthritis - October 2011 update. <i>Acta ReumatolÃ³gica Portuguesa</i> , 2011, 36, 385-8.	0.2	13
132	Methotrexate treatment in rheumatoid arthritis: management in clinical remission, common infection and tuberculosis. Results from a systematic literature review. <i>Clinical Rheumatology</i> , 2010, 29, 629-635.	2.2	13
133	Portuguese guidelines for the use of biological agents in rheumatoid arthritis - March 2010 update. <i>Acta ReumatolÃ³gica Portuguesa</i> , 2010, 35, 95-8.	0.2	4
134	Cardiovascular risk profile in systemic lupus erythematosus and rheumatoid arthritis: a comparative study of female patients. <i>Acta ReumatolÃ³gica Portuguesa</i> , 2010, 35, 325-32.	0.2	19
135	Tumor Necrosis Factor- α 308 Genotypes Influence Inflammatory Activity and TNF- α Serum Concentrations in Children with Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2009, 36, 837-842.	2.0	23
136	Predictors of Damage Progression in Portuguese Patients with Systemic Lupus Erythematosus. <i>Annals of the New York Academy of Sciences</i> , 2009, 1173, 822-828.	3.8	7
137	Validation of the Spanish, Portuguese and French versions of the Lupus Damage Index questionnaire: data from North and South America, Spain and Portugal. <i>Lupus</i> , 2009, 18, 1033-1052.	1.6	20
138	Interleukin-6 as a key player in systemic inflammation and joint destruction. <i>Autoimmunity Reviews</i> , 2009, 8, 538-542.	5.8	321
139	Assessment of salivary gland function in SjÃ¶gren's syndrome: The role of salivary gland scintigraphy. <i>Autoimmunity Reviews</i> , 2009, 8, 672-676.	5.8	61
140	Undifferentiated connective tissue disease: a seven-center cross-sectional study of 184 patients. <i>Clinical Rheumatology</i> , 2009, 28, 915-921.	2.2	55
141	Replication of recently identified systemic lupus erythematosus genetic associations: a case-control study. <i>Arthritis Research and Therapy</i> , 2009, 11, R69.	3.5	131
142	Use of Hyperspectral Remote Sensing to Evaluate Efficacy of Aquatic Plant Management. <i>Invasive Plant Science and Management</i> , 2009, 2, 216-229.	1.1	33
143	Metabolic syndrome, inflammation and atherosclerosis - the role of adipokines in health and in systemic inflammatory rheumatic diseases. <i>Acta ReumatolÃ³gica Portuguesa</i> , 2009, 34, 590-8.	0.2	15
144	Identification of invasive vegetation using hyperspectral remote sensing in the California Delta ecosystem. <i>Remote Sensing of Environment</i> , 2008, 112, 4034-4047.	11.0	272

#	ARTICLE	IF	CITATIONS
145	Recommendations for the diagnosis and treatment of latent and active tuberculosis in inflammatory joint diseases candidates for therapy with tumor necrosis factor alpha inhibitors â€“ March 2008 update. Revista Portuguesa De Pneumologia, 2008, 14, 271-283.	0.7	11
146	RecomendaÃ§Ãµes para o diagnÃ³stico e tratamento das tuberculosas latente e activa nas doenÃ§as inflammatÃ³rias articulares candidatas a terapÃ©utica com fÃ¡rmacos inibidores do factor de necrose tumoral alfa. RevisÃ£o de MarÃ§o de 2008**O presente artigo foi publicado simultaneamente in Acta Reumatol Port 2008;33:77-85 This article has been copublished in Acta Reumatol Port 2008; 33: 77-85. Revista Portuguesa De Pneumologia, 2008, 14, 271-283.	0.7	6
147	Recommendations for the diagnosis and treatment of latent and active tuberculosis in inflammatory joint diseases for candidates for therapy with tumor necrosis factor alpha inhibitors-March 2008 update. Revista Portuguesa De Pneumologia, 2008, 14, 271-83.	0.7	1
148	RecomendaÃ§Ãµes para diagnÃ³stico e tratamento da tuberculose latente e activa nas doenÃ§as inflammatÃ³rias articulares candidatas a tratamento com fÃ¡rmacos inibidores do factor de necrose tumoral alfa. Revista Portuguesa De Pneumologia, 2006, 12, 603-613.	0.7	21
149	Exercise stress echocardiography for detection of pulmonary arterial hypertension in a patient with systemic sclerosis. Revista Portuguesa De Cardiologia, 2006, 25, 199-203.	0.5	5
150	CaracterÃsticas clÃnicas y pronÃ³stico de los pacientes con fibrosis pulmonar que ingresan en cuidados intensivos por insuficiencia respiratoria. AnÃ¡lisis de 20 casos. Medicina ClÃnica, 2003, 121, 63-67.	0.6	6
151	Idiopathic multicentric osteolysis: A rare disease mimicking juvenile chronic arthritis. Clinical Rheumatology, 1996, 15, 97-98.	2.2	12
152	Neural cell adhesion molecule is expressed by smooth muscle cells during the development of the rat vascular system. Journal of Neurocytology, 1989, 18, 809-817.	1.5	9